N/A N=40 Surgical Theater's Surgery Rehearsal Platform
Cerebral Aneurysm Unruptured · Cerebral Aneurysm Ruptured
Primary: Aneurysm Clip Time
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=54 Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
Postoperative Nausea and Vomiting
Primary: PONV Incidence — 12 participants
N/A N=30 The MOTHER (Mobile Technologies to Help Enhancing Regular Physical Activity) Trial for Pregnant Women
Physical Activity
Primary: Physical Activity Monitor Measured Steps — 1166.6; 1062.6; 1092.1; 804.3 step
Phase 2 N=14 Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
Hematologic Malignancies · Disorder Related to Transplantation · Hematopoietic Malignancy
Primary: Event Free Survival (EFS) for Research Participants — 4 Participants
Phase 3 N=56 Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
Nocturia
Primary: The Pearson Correlation Coefficient Between Change From Baseline to Month 1 in Number of Nocturnal Voids and Change From Baseline to Month 1 in Nocturia Impact (NI)…
Phase 2 N=191 Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Atrophy, Geographic
Primary: Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye — -0.52; -0.94; -0.99; -0.96 square millimeter (m^2)
N/A N=140 A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy
Biliary Atresia
Primary: The Percentage of Patients With Serum Total Bilirubin <1.5 mg/dL and With Native Liver at 6 Months After Portoenterostomy — 58.6; 48.6 percentage of participants — p=0.43
N/A N=30 InterStim® Sacral Nerve Modulation Cycling Study
Urinary Urge Incontinence
Primary: Number of Urinary Urge Incontinent (UUI) Episodes Per Day - Randomized Portion — 1.64; 1.82; 1.44; 1.76 Number of UUI episodes/ Day — p=0.3773
Phase 3 N=18 Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion
Healthy · Hypoxia
Primary: SpO2 Accuracy During Motion Conditions - MaxA Sensor — 1.78 Accuracy Root Mean Square
Phase 2 N=94 Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
Molluscum Contagiosum
Primary: Number of Subjects Who Achieve Complete Clearance at 6 Weeks — 10; 7; 2; 3 Participants
N/A N=1,588 Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
Drug Use Disorders · Drug Abuse · Drug Addiction
Primary: Proportion With Prescription Opioid Use Disorder (Defined by DSM5 Criteria). — 0.215; 0.239 proportion of COT patients
N/A N=12 Lactic Acidosis During and After Seizures
Epilepsy
Primary: Salivary Lactic Acid Levels With Seizures — 8.16 mmol/L
N/A N=200 Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects
Dry Eye
Primary: Change From Baseline in Corneal Staining at All Study Time Points — -2.7; -4.0 units on a scale
Phase 2 N=87 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Adult Rhabdomyosarcoma · Childhood Alveolar Rhabdomyosarcoma · Childhood Pleomorphic Rhabdomyosarcoma
Primary: Event Free Survival Probability — 0.23; 0.43 Probability — p=0.0124
Phase 3 N=64 IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders